Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2019.098 | Characterization of the anti-metastatic function of POU4F3 in pancreatic ductal adenocarcinoma and delineate its underlying mechanisms |
Dr. CHEN Yangchao 陳揚超 |
| 2016.217 | Identification of Novel Tumor Suppressor Long Non-coding RNAs epigenetically silenced in Hepatocellular Carcinoma |
Dr. CHEN Yangchao 陳揚超 |
| 2017.232 | Genome-wide identification of circular RNAs with critical roles in pancreatic ductal adenocarcinoma |
Dr. CHEN Yangchao 陳揚超 |
| 2013.163 | Identification and functional characterization of long non-coding RNAs associated with pancreatic ductal adenocarcinoma | Dr Chen Yangchao |
| 2010.178 | Regulation of miroRNA-34a expression by EZH2 in pancreatic ductal adenocarcinoma | DR Chen Yangchao |
| 2009.138 | Regulation of S100P expression by IL-6 pancreatic ductal adenocarcinoma | DR Chen Yangchao |
| 2009.136 | Role of Beta-arrestin in HIV infection and heroin addiction | DR Chen Yangchao |
| 2009.133 | Investigation of the Contribution of miR-29 in the Muscle Regeneration of Duchenue Muscular Dystrophy | DR Chen Yangchao |
| 2010.593 | Functional characterization of EZH2/microRNA-218 interaction in pancreatic ductal adenocarcinoma | DR Chen Yangchao |
| 2010.196 | Development of HPV therapeutic vaccine and related immunotherapy for treating cervical cancer | DR Chen Yangchao |
| 2023.673 | Effect of A Self-Regulation Promoting Education Program on Adherence to Oral Anticancer Agents among Patients with Gastrointestinal Tract Cancer: A Randomized Controlled Trial |
Ms. CHEN Yongfeng 陈永凤 |
| 2016.556 | Quantification of breast milk trans fatty acids and trans fat intake by Hong Kong lactating women |
Dr. CHEN Zhen Yu 陳振宇 |
| 2017.143 | Association between oral microbiome, HPV and human epigenetic events in head and neck squamous cell carcinoma | Prof. CHEN Zigui |
| 2018.022 | Structure and diversity of gastrointestinal (oral and stool) microbial communities of companion animals impacting on human counterparts |
Prof. CHEN Zigui 陳子桂 |
| 2016.186 | Evolutionary dynamics and genetic basis of carcinogenicity of primate papillomaviruses | Prof. CHEN Zigui |
| 2025.016 | Unravelling the Impact of Oral Microbiota Dysbiosis and HPV on Genomic Architecture and Tumor-Associated Immune System in Oropharyngeal Squamous Cell Carcinoma (OPSCC) |
Prof. CHEN Zigui 陳子桂 |
| 2020.705 | Associations between human microbiome and host epigenetic and genetic events in esophageal squamous cell carcinoma (ESCC) using multi-omics approaches |
Prof. CHEN Zigui 陳 子 桂 |
| 2020.001 | Genomic and Functional Characterization of Oral Microbiome Associated with Head and Neck Squamous Cell Carcinoma |
Prof. CHEN Zigui 陳子桂 |
| 2019.036 | Dissecting the role of Fusobacterium nucleatum in head and neck squamous cell carcinoma by genomics and functional approaches |
Prof. CHEN Zigui 陳子桂 |
| 2021.681 | Origin and evolutionary adaptation of the carcinogenicity of human papillomaviruses: evaluation of human and non-human primate PV E6 and E7 oncogenes interacting with host proteomes |
Prof. CHEN Zigui 陳子桂 |
| 2022.554 | Host-Microbiota Interactions Related to HPV(+) and HPV(-) Oropharyngeal Squamous Cell Carcinoma (OPSCC) |
Prof. CHEN Zigui 陳子桂 |
| 2022.553 | Genetic and Epigenetic Abnormalities Associated with Dysbiosis of the Human Microbiota in Esophageal Squamous Cell Carcinoma (ESCC) |
Prof. CHEN Zigui 陳子桂 |
| 2023.637 | Understanding the Role of Oral Microbiota Dysbiosis in the Pathogenesis of Oral Cavity Squamous Cell Carcinoma (OSCC) through Dysregulation of Epithelial-Mesenchymal Transition (EMT)-related Pathways |
Prof. CHEN Zigui 陳子桂 |
| 2021.671 | Characterization of Genomic and Functional Features of Human Microbiome Associated with Oral Cavity Squamous Cell Carcinoma using Multi-Omics Approaches |
Prof. CHEN Zigui 陳子桂 |
| 2019.276 | To develop an evidence-based training programme for improving infection control knowledge and skills related to multi-drug resistance organisms (MDROs) transmission during enteral feeding among hospital nurses. |
Miss CHENG Wai Yan 鄭慧恩 |
| 2018.576 | Molecular and functional characterization of the immunoregulatory CCRK-mTOR pathway in NAFLD-associated hepatocellular carcinoma |
Prof. CHENG Alfred Sze Lok 鄭詩樂 |
| 2018.411 | Deciphering Enhancer Regulation of Tumor Immune Evasion to Develop New Combination Immunotherapies |
Prof. CHENG Alfred Sze Lok 鄭詩樂 |
| 2015.187 | Dissecting an inflarnmatory-CCRK circuitry m non-alcoholic fatty liver disease-related hepatocarcinogenesis |
Prof. CHENG Alfred Sze Lok 鄭詩樂 |
| 2018.051 | Functional dissection of fibrosis-associated monocytic myeloid derived suppressor cells (M-MDSCs) in hepatocellular carcinoma |
Prof. CHENG Alfred Sze Lok 鄭詩樂 |
| 2016.230 | Co-targeting the AKT and EZH2 epigenetic pathways in hepatitis B virus-related hepatocellular carcinoma |
Prof. CHENG Alfred Sze Lok 鄭詩樂 |
| 2023.105 | The role of macrophage lipid transfer in driving immunotherapy resistance of hepatocellular carcinoma cells | Prof. CHENG Alfred Sze Lok |
| 2021.227 | Advancing Precision Immunotherapy of Hepatocellular Carcinoma by Single-cell Multi-Omics |
Prof. CHENG Alfred Sze Lok 鄭詩樂 |
| 2014.076 | Mechanistic characterization of liver cancer epigenome mediated by androgen receptor signaling | Dr. CHENG Alfred Sze Lok |
| 2016.482 | Functional genomic characterization of human placental development and pathology for noninvasive biomarker discovery |
Dr. CHENG Alice Suk Hang 曾卓豪 |
| 2007.435 | Comparison of Oral Prednisolone/Paracetamol and Oral Indomethacin / Paracetamol Combination Therapy in the Treatment of Acute Gout like Arthritis: A Multi-Centre, Double-Blind, Randomized, Controlled Trial | Dr. Cheng Chi Hung |
| 2008.466 | Comparison of Oral Prednisolone and Oral Indomethacin in the Treatment of Acute Gout-like Arthritis: A Multi-centre, Double-Blind, Randomized Trial | Dr. Cheng Chi Hung |
| 2011.133 | A Traditional Chinese medicine formula for bones and joints care for chronic pain of lower limb: A Randomized Control Trial | Prof Cheng Christopher Hon Ki |
| 2013.375 | Pathophysiology of oropharyngeal dysphagia in post-irradiation nasopharyngeal carcinoma patients in relation to penetration-aspiration - A pilot study | Mr CHENG Dennis Tze-ho |
| 2015.553 | Intergroup trial for children or adolescents with B-cell NHL or B-AL: Evaluation of Rituximab efficacy and safety in high risk patients |
Dr. CHENG Frankie Wai Tsoi 鄭偉才醫生 |
| 2017.371 | TREATMENT OUTCOME OF HEPATOBLASTOMA AND PAEDIATRIC HEPATOCELLULAR CARCINOMA IN HONG KONG | Dr. CHENG Frankie Wai Tsoi |
| 2015.413 | Multicenter, open-label, active-controlled, randomized study to evaluate the efficacy and safety of an age-and body weight-adjusted rivaroxaban regimen compared to standard of care in children with acute venous thromboembolism | Dr. CHENG Frankie Wai Tsoi |
| 2020.246 | Outcome of Paediatric Chronic Myeloid Leukemia in Hong Kong | Dr. CHENG Frankie Wai Tsoi |
| 2021.380 | Resting and Dynamic Right Ventricular-Pulmonary Arterial Coupling in Childhood Cancer Survivors |
Dr. CHENG Frankie Wai Tsoi 鄭偉才 |
| 2007.472 | International, Multi-Center, Randomized, Double Blind Study to Compare the Overall Mortality in Acutely Ill Medical Patients Treated with Enoxaparin versus Placebo in Addition to Graduated Elastic Stockings | Professor Cheng Gregory |
| 2008.513 | An International, Multicenter, Randomized, Double-blind Study of Vorinostat (MK-0683) or Placebo in Combination with Bortezomib in Patients with Multiple Myeloma | Prof Cheng Gregory |
| 2009.186 | A Phase I/IIa Safety and Pharmacokinetic Study of Intravenous FIXFc Administration to Previously Treated Hemophilia B Patients | Prof. Cheng Gregory |
| 2010.176 | B-LONG: An Open-Label, Multicenter Evaluation of the Safety, Pharmacokinetics, and Efficacy of Recombinant, Long-acting Coagulation Factor IX Fc fusion (rFIXFc) in the Prevention and Treatment of Bleeding in Previously Treated Subjects With Severe Hemophilia B | Professor Cheng Gregory |
| 2009.220 | Study PMA112509, a Phase I/II Study of Eltrombopag in Thrombocytopenic Subjects with Advanced Myelodysplastic Syndrome (MDS) or secondary Acute Myeloid Leukemia after MDS (sAML/MDS) | Professor Cheng Gregory |
| 2009.573 | An Open-label, Phase 1 Study of R-CVP or R-GDP in Combination With Inotuzumab Ozogamicin in Subjects With CD22-Positive Non-Hodgkin’s Lymphoma | Prof Cheng Gregory |
| 2009.588 | A Phase I/Iia, Open-Label, Crossover, Dose-Escalation, and Multi-Center Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Injection of rFVIIIFc in Previously Treated Patients with Severe Hemphilia A | Professor II Cheng Greory |
Page 74 of 262.